SEMINAR

On Saturday, June 15, 2024, at 11:30 AM, a two-hour seminar titled "Polygenic Risk Score: An Innovative Approach in the Prevention and Treatment of Breast and Lung Cancer" will take place. The seminar is organized by the Hellenic Cancer Society in collaboration with DNA Plus, Allelica, and Novogenia, and will be held at the B. & M. Theocharakis Foundation for the Fine Arts & Music (Vassilissis Sofias 9 & Merlin 1, Athens 106 71). 

According to the attached program, the seminar will be moderated by Mr. Evangelos Filopoulos, President of the Hellenic Cancer Society, and Professor Panagiotis Bechrakis, President of the Scientific Committee of the Hellenic Cancer Society. The speakers will include Mr. Florian Schneebauer, a laboratory geneticist; Mr. George Busby, scientific director and co-founder of Allelica; Mr. Drakoulis Giannoukakos, Director of Research at the National Center for Scientific Research Demokritos; and Professor George Patrinos, Professor of Pharmaceutical Biotechnology and Pharmacogenomics at the University of Patras. The seminar will be officially opened by the Minister of Health, Mr. Adonis Georgiadis. 

Mr. Schneebauer's presentation, titled "Comprehensive Review of DNA-Microarray Use Cases in Preventive Genetics: Polygenic Risk Scores and Pharmacogenetics," will provide an overview of DNA microarray technology, which revolutionizes clinical genetics by enabling the simultaneous analysis of thousands of genetic variations. This technology is used to develop pharmacogenomic (PGx) tests and polygenic risk scores (PRS) that enhance disease prevention and treatment. PGx tailors treatments to a patient's DNA, increasing safety and efficacy, while PRS identifies individuals at high risk for diseases, allowing for early intervention. 

Mr. George Busby will speak on "Integrating Common Genetic Risk into Breast and Lung Cancer Risk Prediction Models." His lecture will emphasize the importance of risk assessment in cancer prevention and treatment, focusing on models that combine traditional risk factors with genetic information (PRS). These models allow doctors to more accurately calculate